Gliomas represent nearly 80% of all malignant primary brain tumors. Despite multimodal therapeutic approaches encompassing maximal safe resection, chemotherapy, and radiotherapy, recurrence is nearly inevitable, and long-term survival rates remain dismal, particularly for high-grade gliomas such as glioblastoma.
While the epidermal growth factor receptor (EGFR) is a well-established and frequently amplified oncogenic driver in glioma, emerging evidence highlights the critical role of metabolic reprogramming in tumorigenesis. Among these metabolic shifts, choline metabolism, pivotal for membrane biosynthesis and cell signaling, has garnered significant attention. Choline kinase alpha (CHKA), the enzyme catalyzing the first committed step in the Kennedy pathway for phosphatidylcholine synthesis, has been implicated in promoting growth and survival across various cancer types.
However, the precise mechanistic link between CHKA and the canonical EGFR signaling axis in glioma pathogenesis has remained elusive. This study was therefore designed to elucidate how CHKA contributes to glioma malignancy and to investigate the potential cooperative interplay between CHKA and EGFR in driving tumor progression, specifically through the activation of the mitogen-activated protein kinase (MAPK) pathway. This study, led by Deputy Chief Physician Dr. Yourui Zou from General Hospital of Ningxia Medical University, was published in Volume 139, Issue 5 of the journal Chinese Medical Journal on March 05, 2026.
To address these questions, the research team employed a comprehensive, multi-platform strategy integrating advanced genomic, proteomic, and functional assays. Single-cell RNA sequencing of clinical glioma specimens provided high-resolution transcriptomic data, revealing a striking co-expression pattern of CHKA and EGFR within specific, highly malignant cellular subpopulations, suggesting a potential functional synergy. Subsequent mass spectrometry analysis of co-immunoprecipitated complexes and chromatin immunoprecipitation (ChIP) assays furnished direct biochemical evidence, confirming a physical interaction between CHKA and EGFR proteins within glioma cells. Building on this discovery, a series of in vitro cell-based investigations was conducted. These experiments demonstrated that CHKA not only upregulates the total protein levels of EGFR but, more importantly, significantly enhances its phosphorylation at key tyrosine residues. This CHKA-mediated hyperactivation of EGFR translated into potent functional consequences, markedly boosting glioma cell proliferation, migration, and invasive capacity. The critical nature of this axis was further underscored in vivo using orthotopic xenograft mouse models. Genetic knockdown of CHKA led to a profound suppression of tumor growth, reducing tumor volume by approximately 66% and tumor weight by ~79%. Crucially, this tumor-suppressive effect was effectively rescued by concomitant overexpression of EGFR, confirming CHKA's function operates primarily through the EGFR pathway.
The collective findings from this rigorous investigation establish a robust molecular cascade: CHKA and EGFR are highly co-expressed in aggressive glioma cells, and their expression levels positively correlate with advanced tumor grade and poor patient prognosis. Mechanistically, CHKA directly interacts with and stabilizes EGFR, promoting its phosphorylation and subsequent activation of the downstream MAPK signaling cascade, including key effectors such as ERK, p38, and JNK. Silencing CHKA disrupts this axis, significantly impairing glioma cell growth and migration both in cultured cells and in animal models. The dramatic tumor inhibition observed upon CHKA knockdown in mice, and its reversal by EGFR overexpression, provides compelling in vivo validation.
This study is the first to demonstrate a direct protein-protein interaction between CHKA and EGFR and to establish their cooperative role in activating the oncogenic MAPK pathway in glioma. The findings position the CHKA/EGFR/MAPK axis as a pivotal driver of glioma progression and a promising, novel therapeutic target. Given the limited efficacy of existing EGFR-targeted monotherapies, often due to compensatory resistance mechanisms, this research suggests a paradigm-shifting combinatorial strategy. Simultaneously inhibiting CHKA to disrupt its upstream regulatory and stabilizing function on EGFR, alongside direct EGFR-targeted therapies, could potentially yield a synergistic effect, overcoming treatment resistance and offering a more effective therapeutic avenue for this devastating disease.
***
Reference
DOI: 10.1097/CM9.0000000000003977
About Dr. Yourui Zou from General Hospital of Ningxia Medical University
Deputy Chief Physician, Department of Neurosurgery, General Hospital of Ningxia Medical University, Doctor of Medicine, and Master's Supervisor. Member of the Neuro-Oncology Committee of the China Anti-Cancer Association, Secretary and Member of the Seventh Committee of the Neurosurgery Branch of the Ningxia Medical Association, Secretary and Member of the Second Committee of the Neurosurgery Branch of the Ningxia Medical Doctor Association, and Secretary of the Neuro-Oncology Committee of the Ningxia Anti-Cancer Association.
National top-twenty finalist in a pediatric neurosurgery competition. Principal investigator of a provincial Natural Science Foundation project and participant in national/provincial research. Author of 8 publications.
Funding information
This study was supported by grants from the Ningxia Natural Science Foundation project (Nos. 2022AAC03592; 2022AAC03559), Central Government Guided Local Science and Technology Development Fund Project (No. 2024FRD05099) and the National Natural Science Foundation of China (No. 82460469).
Chinese Medical Journal
Experimental study
Animals
Choline kinase α interacts with epidermal growth factor receptor to activate the mitogen-activated protein kinase pathway and contributes to glioma tumorigenesis
5-Mar-2026
The authors declare no conflicts of interest